The 2018 Diabetes Canada Clinical Practice Guidelines provide clinicians with recommendations for the selection of therapy for type 2 diabetes. The guidelines provide a recommendation to customize antihyperglycemic agents (AHAs) based on patient and AHA properties.
This event is an accredited group learning activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program. It is approved by the Canadian Society of Endocrinology and Metabolism for a maximum of 1 credit(s).
Ronald Goldenberg, MD, FRCPC, FACE
Harpreet Bajaj, MD, MPH, FACE
Bertha Wong, MD, FRCPC
Upon successful completion of this continuing education activity, the clinician will be better able to:
- Review the current evidence supporting the role of antihyperglycemic agents (AHA) for reducing cardiovascular and renal outcomes
- Summarize the importance of weight in the management of type 2 diabetes and the selection of antihyperglycemic agents
- Explain the pros and cons of basal insulin, GLP-1 receptor agonist (GLP-1 RA), and fixed dose insulin/GLP-1 RA as the first injectable therapy
- Develop a treatment strategy for the patient who is not reaching glycemic targets with basal insulin therapy +/- noninsulin AHAs